Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 199 participants.
Also called NCT05966272
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 199 participants
- Registry
-
NCT05966272
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05966272. Randomized; triple masking; primary purpose treatment. Start 2023-08-12 (actual); primary completion 2024-09-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HRS9531 injection
- Intervention (Drug)
- HRS9531 injection Placebo
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05966272- Content hash
068fa1af287b0c7a6e7f8e254c1cdd5dbac328c0cc76d84bb2371d1a86e65991